A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study to Assess the Efficacy and Safety of Clavulanic Acid vs. Placebo for the Treatment of Cocaine Use Disorder

Date Added
December 19th, 2022
PRO Number
Pro00125021
Researcher
Aimee McRae-Clark

List of Studies


Keywords
Substance Use
Summary

This pilot study is to research whether or not the investigational drug clavulanic acid, along with medication management, can help people with cocaine use disorder who are interested in quitting. Participants who are eligible after screening visits are randomly assigned to take clavulanic acid or placebo for twelve weeks and will meet with study staff three times a week for urine drug screens.

Institution
MUSC
Recruitment Contact
Lisa Nunn
843-792-0476
jenkinli@musc.edu

A Phase 2, Multicenter, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Clinical Trial of Titrating Doses of Nabilone with Gabapentin for the Mitigation of Cannabis Withdrawal Symptoms

Date Added
September 14th, 2022
PRO Number
Pro00122680
Researcher
Aimee McRae-Clark

List of Studies


Keywords
Substance Use
Summary

This research study will include heavy, long-term cannabis users with moderate to severe use desire who want or need to discontinue cannabis use and have previously had symptoms of cannabis withdrawal. Subjects participating in this research study will receive either PP-01 higher dose or lower dose (combination of nabilone and gabapentin in a varied amount), nabilone only, gabapentin only or placebo (inactive substance). This study will assess whether the study drugs help to lessen or alleviate cannabis withdrawal symptoms in study subjects.

Institution
MUSC
Recruitment Contact
Lisa Nunn
843-792-0476
jenkinli@musc.edu

Varenicline for the Treatment of Cannabis and Tobacco Use Disorders in Veterans

Date Added
September 7th, 2021
PRO Number
Pro00112888
Researcher
Aimee McRae-Clark

List of Studies


Keywords
Substance Use
Summary

After initial eligibility screening, Veterans who use both cannabis and tobacco will be randomly assigned to receive either varenicline (Chantix) or placebo for 12 weeks. Participants will attend weekly visits to provide breath and urine samples for testing, fill out questionnaires, and meet with study staff about medication compliance.

Institution
MUSC
Recruitment Contact
Lisa Nunn
843-792-0476
jenkinli@musc.edu

Varenicline as a Treatment for DSM 5 Cannabis Use Disorder in Adults

Date Added
July 2nd, 2019
PRO Number
Pro00089933
Researcher
Aimee McRae-Clark

List of Studies


Keywords
Drug Studies, Substance Use
Summary

Marijuana is the most commonly used illicit drug. There is high demand for effective interventions for cannabis use disorder, yet few specific treatments for have been developed. This study will evaluate the efficacy of varenicline for reducing marijuana use in people who use marijuana frequently.

Institution
MUSC
Recruitment Contact
Amanda Wagner
843-792-0484
wagne@musc.edu

Impact of progesterone on stress reactivity and cannabis use

Date Added
September 4th, 2018
PRO Number
Pro00081360
Researcher
Aimee McRae-Clark

List of Studies


Keywords
Drug Studies, Psychiatry
Summary

The purpose of the study is to determine if the hormone progesterone affects marijuana users' stress response and marijuana use. Participation lasts approximately three weeks. During the first week, participants are randomly assigned to take either progesterone or placebo and remain abstinent from marijuana. They return at the end of the week to participate in a stress task. Throughout the three weeks, participants complete "CREMA" sessions (Cue Reactivity Ecologic Momentary Assessment) three times a day. These sessions include looking at stressful and neutral pictures and rating stress and craving.

Institution
MUSC
Recruitment Contact
Lisa Nunn
843-792-0476
jenkinli@musc.edu

A Phase 2B, 8-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Tolerability of the Fatty Acid Amide Hydrolase (FAAH) Inhibitor PF-04457845 in Adults with DSM-5 Current Cannabis Use Disorder (CUD)

Date Added
July 3rd, 2018
PRO Number
Pro00079439
Researcher
Aimee McRae-Clark

List of Studies


Keywords
Drug Studies, Substance Use
Summary

This study will examine whether the investigational medication PF-0447845 is safe and effective in reducing cannabis use among people who frequently use cannabis. This is a 14-week, randomized, double-blind, placebo-controlled outpatient clinical trial that will be conducted at 4 research sites in the eastern U.S.

Institution
MUSC
Recruitment Contact
Amanda Wagner
843-792-0484
wagne@musc.edu



-- OR --